Discovery and development of ML3000

被引：47

作者：

Stefan Laufer

机构：

[1] University of Tuebingen,Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy

来源：

InflammoPharmacology | 2001年 / 9卷 / 1-2期

关键词：

CYCLOOXYGENASE; 5-LIPOXYGENASE; NSAID; ANTI-INFLAMMATORY; ML3000; [2,2-DIMETHYL-6-(4-CHLOROPHENYL)-7-PHEYNY-2,3-DIHYDRO-1H-PYRROLIZINE-5-YL]-ACETIC ACID; H-PYRROLIZINE; LEUKOTRIENE; GASTROINTESTINAL;

D O I：

10.1163/156856001300248371

中图分类号：

学科分类号：

摘要：

NSAID management of the inflammatory process has focused on reducing the production of inflammatory prostaglandins by inhibiting the cyclooxygenase (COX) enzyme. However, blocking COX also reduces gastroprotective prostaglandins, causing the well-known gastrointestinal side effects. Furthermore, a shunting of arachidonic acid to the 5-lipoxygenase (5-LOX) pathway may also occur, causing an increase in leukotrienes and further GI damage. Several compounds, designed to block both COX and 5-LOX, have failed in clinical trials due to liver toxicity, related to their redox potential. ML3000 is a new pyrrolizine compound resulting from a systematic approach to design a non-redox substrate analog of arachidonic acid that inhibited both COX and 5-LOX. Pharmacodynamic studies determined that ML3000 is a dual inhibitor of COX and 5-LOX, with analgesic, anti-inflammatory, antipyretic, antiplatelet, and anti-bronchoconstrictive activity, and minimal gastrointestinal side effects. Clinical studies show efficacy in osteoarthritis and excellent gastrointestinal safety. ML3000 is now in phase III development.

引用

页码：101 / 112

页数：11

共 35 条

[1]

Algate D. R.(1995)General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals Arzneim.-Forsch./ Drug Research 45 2-718

[2]

Augustin J.(1990)Pharmacokinetics, pharmacodynamics, and mini-mum effective clinical dose of intravenous nicardipine Clin. Pharmacol. Ther. 47 706-162

[3]

Atterson P. R.(1988)Anti-inflammatory 2,3-dihydro-1H-pyrrolizine. 13. Isomeric (diaryl-dihydropyrrolizinyl) acetic acids and 2-(diaryldihydropyrrolizinyl)-ethanols Arch. Pharm. 321 159-4

[4]

Cook E.(1990)NSAID induced ulcers. An emerging epidemic? J. Rheuma-tot. 17 1-918

[5]

Clifton G. G.(1990)Antioxidant-based inhibitors of leukotriene biosynthesis. The discovery of 6-[1-[2-(hydroxymethyl)phenyl]-1-propen-3-yl]-2,3-dihydro-5-benzofuranol, a potent topical antiin' ammatory agent J. Med. Chem. 33 908-85

[6]

Vargas R.(1984)Pharmacological properties of a new anti-inflammatory compound, alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolactone (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase Jpn J. Pharmacol. 36 77-747

[7]

Dannhardt G.(1993)Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs Gut 34 742-1897

[8]

Lehr M.(1994)6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase J. Med. Chem 37 1894-2368

[9]

Gabriel S. E.(1990)Synthesis and quantitative structure-activity relationships of diclofenac analogues J. Med. Chem. 33 2358-580

[10]

Bombardier C.(1993)Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage Agents Action 39 C25-998

← 1 2 3 4 →